Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1909 to 1910 of 1910 entries
Sorted by: Best Match Show Resources per page
KAT2B is an immune infiltration-associated biomarker predicting prognosis and response to immunotherapy in non-small cell lung cancer.

Investigational new drugs

Zhou X, Wang N, Zhang Y, Yu H, Wu Q.
PMID: 34499335
Invest New Drugs. 2022 Feb;40(1):43-57. doi: 10.1007/s10637-021-01159-6. Epub 2021 Sep 09.

BACKGROUND: Over the past few years, dramatic breakthroughs in the field of tumor immunotherapy with immune checkpoint inhibitors (ICIs) have made a therapeutic revolution for non-small cell lung cancer (NSCLC). While only some patients present a favorable response to...

Cite
Zhou X, Wang N, Zhang Y, et al. KAT2B is an immune infiltration-associated biomarker predicting prognosis and response to immunotherapy in non-small cell lung cancer. Invest New Drugs. 2021;40(1):43-57doi: 10.1007/s10637-021-01159-6.
Zhou, X., Wang, N., Zhang, Y., Yu, H., & Wu, Q. (2022). KAT2B is an immune infiltration-associated biomarker predicting prognosis and response to immunotherapy in non-small cell lung cancer. Investigational new drugs, 40(1), 43-57. https://doi.org/10.1007/s10637-021-01159-6
Zhou, Xue, et al. "KAT2B is an immune infiltration-associated biomarker predicting prognosis and response to immunotherapy in non-small cell lung cancer." Investigational new drugs vol. 40,1 (2022): 43-57. doi: https://doi.org/10.1007/s10637-021-01159-6
Zhou X, Wang N, Zhang Y, Yu H, Wu Q. KAT2B is an immune infiltration-associated biomarker predicting prognosis and response to immunotherapy in non-small cell lung cancer. Invest New Drugs. 2022 Feb;40(1):43-57. doi: 10.1007/s10637-021-01159-6. Epub 2021 Sep 09. PMID: 34499335.
Copy Download .nbib Format: NLM
The value of single or combined use of pleural fluid interferon gamma release assay in the diagnosis of tuberculous pleurisy.

Tropical medicine & international health : TM & IH

Tong X, Li Z, Zhao J, Liu S, Fan H.
PMID: 34297877
Trop Med Int Health. 2021 Nov;26(11):1356-1366. doi: 10.1111/tmi.13659. Epub 2021 Aug 01.

OBJECTIVE: Tuberculous pleurisy (TP) is a common disease of extrapulmonary tuberculosis, but its diagnosis is challenging. Recently, studies have found that the pleural fluid interferon gamma release assay (PF-IGRA) has important diagnostic value in TP, but the sample size...

Cite
Tong X, Li Z, Zhao J, et al. The value of single or combined use of pleural fluid interferon gamma release assay in the diagnosis of tuberculous pleurisy. Trop Med Int Health. 2021;26(11):1356-1366doi: 10.1111/tmi.13659.
Tong, X., Li, Z., Zhao, J., Liu, S., & Fan, H. (2021). The value of single or combined use of pleural fluid interferon gamma release assay in the diagnosis of tuberculous pleurisy. Tropical medicine & international health : TM & IH, 26(11), 1356-1366. https://doi.org/10.1111/tmi.13659
Tong, Xiang, et al. "The value of single or combined use of pleural fluid interferon gamma release assay in the diagnosis of tuberculous pleurisy." Tropical medicine & international health : TM & IH vol. 26,11 (2021): 1356-1366. doi: https://doi.org/10.1111/tmi.13659
Tong X, Li Z, Zhao J, Liu S, Fan H. The value of single or combined use of pleural fluid interferon gamma release assay in the diagnosis of tuberculous pleurisy. Trop Med Int Health. 2021 Nov;26(11):1356-1366. doi: 10.1111/tmi.13659. Epub 2021 Aug 01. PMID: 34297877.
Copy Download .nbib Format: NLM
Showing 1909 to 1910 of 1910 entries